Effects of 4 weeks’ administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations (Q40877224)
Jump to navigation
Jump to search
scientific article published on November 1, 1997
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Effects of 4 weeks’ administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations |
scientific article published on November 1, 1997 |
Statements
1 reference
Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations (English)
1 reference
Effects of 4 weeks’ administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations (English)
1 reference
R. G. Thompson
L. Pearson
1 November 1997
1 reference
1 reference
1 reference
1 reference
40
1 reference
11
1 reference
1278-1285
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference